spacer
home > pmps > winter 2018 > uncommon codes
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Uncommon Codes

With deadlines approaching in Europe, the US, and other countries, pharmaceutical companies and CMOs on both sides of the Atlantic are scrambling to implement viable serialisation solutions to comply with regulatory requirements, such as the Falsified Medicines Directive and the Drug Supply Chain Security Act.

While a lot of time and resources have already been expended on line-site implementation, connecting the dots with sufficient infrastructure – both at the enterprise level and along the ensuing supply chain – is now critical. Today, serialisation compliance clearly affects aspects of a business far beyond the production line. From manufacturing through to the point of dispensation, great demands exist to exchange information between trading partners and stakeholders to address both regulatory requirements and business challenges.

Ensuring Unique Numbers


The life of a serialised product begins with the generation of a unique serial number. When producing medicines for markets where serial numbers are not created and managed by authorities, the need for generating and exchanging serial numbers depends on a pharma company’s size, structure, and business strategy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Pavel Lotkov is Product Director for Adents. Formerly with Eli Lilly, Pavel has more than 16 years of information technology experience and possesses a deep understanding of business operations at large pharma companies. As solution implementation and adoption lead, Pavel focused on regulatory requirements and business process analysis, risk impact assessment, system validation, and solution provider management. Pavel was instrumental in providing tactical and strategic support to Lilly’s functional areas impacted by serialisation.
spacer
Pavel Lotkov
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Datwyler celebrates official opening of its new production plant with First Line standard in Middletown, Del

• The new facility in Middletown, Del., is Datwyler’s third facility with First Line standard which will be catering to the markets in North and South America • Approximately 120 jobs will be created, with the majority staffed from the local community • With the Middletown facility, Datwyler will be able to increase its global First Line production by 50 percent by 2020 • First Line is specially designed to manufacture biotech and pharmaceutical elastomer components in a fully integrated good manufacturing practice (GMP) environment
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

CPhI & P-MEC India 2018

12-14 December 2018, India Expo Mart, New Delhi, India

CPhI & P-MEC India (December 12-14, 2018) – organised by UBM (part of Informa PLC) – announces that the 12th edition of Asia’s largest Pharma exhibition is moving to the India Expo Mart, New Delhi. The new venue will see the exhibition now hosted in a single venue, bringing it closer to the Indian regulatory and legislative capital. New Delhi is also the country’s main international transport hub and will encourage an increased international attendance. In total, more than 50,000 people from 122 countries are expected, along with nearly 1,500 exhibitors.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement